Current challenges in the development of vaccines for pneumonic plague

References

• Butler T. Plague and Other Yersinia Infections. Greenough WB, Merigan TC (Eds). Plenum Press, New York, USA (1983).
   Google Scholar
• Prentice MB, Rahalison L. Plague. Lancet369(9568), 1196–1207 (2007).
   PubMed Web of Science ®Google Scholar
• Yersin A. La peste bubonique a Hong Kong. Ann. Inst. Pasteur (Paris)8, 662–667 (1894).
   Google Scholar
• Achtman M, Zurth K, Morelli G et al.Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis.Proc. Natl Acad. Sci. USA96(24), 14043–14048 (1999).
   PubMed Web of Science ®Google Scholar
• Perry RD, Fetherston JD. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev.10(1), 35–66 (1997).
   PubMed Web of Science ®Google Scholar
• Brubaker RR. Interleukin-10 and inhibition of innate immunity to yersiniae: roles of Yops and LcrV (V antigen). Infect. Immun.71(7), 3673–3681 (2003).
   PubMed Web of Science ®Google Scholar
• Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc. Natl Acad. Sci. USA103(14), 5526–5530 (2006).
   PubMed Web of Science ®Google Scholar
• Lien-Teh W. A Treatise on Pneumonic Plague. League of Nations Health Organisation, Geneva, Switzerland (1926).
   Google Scholar
• Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin. Infect. Dis.40(8), 1166–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Flexner S. The pathology of bubonic plague. Am. J. Med. Sci.122, 396–416 (1901).
   Google Scholar
• Sebbane F, Gardner D, Long D, Gowen BB, Hinnebusch BJ. Kinetics of disease progression and host response in a rat model of bubonic plague. Am. J. Pathol.166(5), 1427–1439 (2005).
   PubMed Web of Science ®Google Scholar
• Lathem WW, Crosby SD, Miller VL, Goldman WE. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc. Natl Acad. Sci. USA102(49), 17786–17791 (2005).
   PubMed Web of Science ®Google Scholar
• Bubeck SS, Cantwell AM, Dube PH. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect. Immun.75(2), 697–705 (2007).
   PubMed Web of Science ®Google Scholar
• Finegold MJ, Petery JJ, Berendt RF, Adams HR. Studies on the pathogenesis of plague. Blood coagulation and tissue responses of Macaca mulatta following exposure to aerosols of Pasteurella pestis.Am. J. Pathol.53(1), 99–114 (1968).
   PubMed Web of Science ®Google Scholar
• Finegold MJ. Pneumonic plague in monkeys. An electron microscopic study. Am. J. Pathol.54(2), 167–185 (1969).
   PubMed Web of Science ®Google Scholar
• Jackson S, Burrows TW. The virulence-enhancing effect of iron on nonpigmented mutants of virulent strains of Pasteurella pestis.Br. J. Exp. Pathol.37(6), 577–583 (1956).
   PubMedGoogle Scholar
• Brubaker RR, Beesley ED, Surgalla MJ. Pasteurella pestis: role of pesticin I and iron in experimental plague. Science149(3682), 422–424 (1965).
   PubMed Web of Science ®Google Scholar
• Une T, Brubaker RR. in vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae. Infect. Immun.43(3), 895–900 (1984).
   PubMed Web of Science ®Google Scholar
• Sodeinde OA, Subrahmanyam YV, Stark K et al. A surface protease and the invasive character of plague. Science258(5084), 1004–1007 (1992).
   PubMed Web of Science ®Google Scholar
• Parent MA, Berggren KN, Kummer LW et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun.73(11), 7304–7310 (2005).
   PubMed Web of Science ®Google Scholar
• Welkos S, Pitt ML, Martinez M et al. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine20(17–18), 2206–2214. (2002).
   PubMed Web of Science ®Google Scholar
• Lathem WW, Price PA, Miller VL, Goldman WE. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science315(5811), 509–513 (2007).
   PubMed Web of Science ®Google Scholar
• Cornelis GR. Yersinia type III secretion: send in the effectors. J. Cell Biol.158(3), 401–408. (2002).
   PubMed Web of Science ®Google Scholar
• Viboud GI, Bliska JB. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu. Rev. Microbiol.59, 69–89 (2005).
   PubMed Web of Science ®Google Scholar
• Heesemann J, Sing A, Trulzsch K. Yersinia’s stratagem: targeting innate and adaptive immune defense. Curr. Opin. Microbiol.9(1), 55–61 (2006).
   PubMed Web of Science ®Google Scholar
• Jawetz E, Meyer KF. Studies on plague immunity in experimental animals. II. Some factors of the immunity mechanism in bubonic plague. J. Immunol.49, 15–30 (1944).
   Google Scholar
• Meyer KF. Immunity in plague: a critical consideration of some recent studies. J. Immunol.64, 139–163 (1950).
   PubMed Web of Science ®Google Scholar
• Rowland S. The morphology of plague bacillus. J. Hyg.13(Plague Suppl. III), 418–422 (1914).
   PubMedGoogle Scholar
• Schutze H. Studies in B. Pestis antigens: I. The antigens and immunity reactions of B. pestis. Br.J. Exp. Pathol.13, 284–288 (1932).
   Google Scholar
• Cavanaugh DC, Randall R. The role of multiplication of Pasteurella pestis in mononuclear phagocytes in the pathogenesis of flea-borne plague. J. Immunol.83, 348–363 (1959).
   PubMed Web of Science ®Google Scholar
• Chen TH, Elberg SS. Scanning electron microscopic study of virulent Yersinia pestis and Yersinia pseudotuberculosis type 1. Infect. Immun.15(3), 972–977 (1977).
   PubMed Web of Science ®Google Scholar
• Du Y, Rosqvist R, Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect. Immun.70(3), 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Winter CC, Cherry WB, Moody MD. An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull. World Health Organ.23, 408–409 (1960).
   PubMedGoogle Scholar
• Friedlander AM, Welkos SL, Worsham PL et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.Clin. Infect. Dis.21(Suppl. 2), S178–S181 (1995).
   PubMed Web of Science ®Google Scholar
• Welkos SL, Davis KM, Pitt LM, Worsham PL, Freidlander AM. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib. Microbiol. Immunol.13, 299–305 (1995).
   PubMedGoogle Scholar
• Davis KJ, Fritz DL, Pitt ML et al. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch. Pathol. Lab. Med.120(2), 156–163 (1996).
   PubMed Web of Science ®Google Scholar
• Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. Plague bacteria target immune cells during infection. Science309(5741), 1739–1741 (2005).
   PubMed Web of Science ®Google Scholar
• Welkos S, Friedlander A, McDowell D, Weeks J, Tobery S. V antigen of Yersinia pestis inhibits neutrophil chemotaxis. Microb. Pathog.24(3), 185–196 (1998).
   PubMed Web of Science ®Google Scholar
• Sing A, Reithmeier-Rost D, Granfors K et al. A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence. Proc. Natl Acad. Sci. USA102(44), 16049–16054 (2005).
   PubMed Web of Science ®Google Scholar
• Reithmeier-Rost D, Hill J, Elvin SJ et al. The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis. Microbes Infect.9(8), 997–1002 (2007).
   PubMed Web of Science ®Google Scholar
• Pouliot K, Pan N, Wang S et al. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis.Infect. Immun.75(7), 3571–3580 (2007).
   PubMed Web of Science ®Google Scholar
• Janssen WA, Surgalla MJ. Plague bacillus: survival within host phagocytes. Science163, 950–952 (1969).
   PubMed Web of Science ®Google Scholar
• Straley SC, Harmon PA. Growth in mouse peritoneal macrophages of Yersinia pestis lacking established virulence determinants. Infect. Immun.45(3), 649–654 (1984).
   PubMed Web of Science ®Google Scholar
• Pujol C, Bliska JB. Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin. Immunol.114(3), 216–226 (2005).
   PubMed Web of Science ®Google Scholar
• Lukaszewski RA, Kenny DJ, Taylor R et al. Pathogenesis of Yersinia pestis infection in BALB/c mice: effects on host macrophages and neutrophils. Infect. Immun.73(11), 7142–7150 (2005).
   PubMed Web of Science ®Google Scholar
• Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA283(17), 2281–2290 (2000).
   PubMed Web of Science ®Google Scholar
• Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet355(9198), 111–113 (2000).
   PubMed Web of Science ®Google Scholar
• Becker AL. Plague outbreak highlighted ongoing problem in Africa. In: CIDRAP News. Center for Infectious Disease Research & Policy, MN, USA (2005)
   Google Scholar
• Alibek K. Biohazard. Random House Inc., NY, USA (1999).
   Google Scholar
• Zilinskas RA. The anti-plague system and the Soviet biological warfare program. Crit. Rev. Microbiol.32(1), 47–64 (2006).
   PubMed Web of Science ®Google Scholar
• Galimand M, Guiyoule A, Gerbaud G et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med.337(10), 677–680 (1997).
   PubMed Web of Science ®Google Scholar
• Guiyoule A, Gerbaud G, Buchrieser C et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg. Infect. Dis.7(1), 43–48 (2001).
   PubMed Web of Science ®Google Scholar
• Hinnebusch BJ, Rosso ML, Schwan TG, Carniel E. High-frequency conjugative transfer of antibiotic resistance genes to Yersinia pestis in the flea midgut. Mol. Microbiol.46(2), 349–354 (2002).
   PubMed Web of Science ®Google Scholar
• Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin. Biol. Ther.4(6), 965–973 (2004).
   PubMed Web of Science ®Google Scholar
• Haffkine WM. Remarks on the plague prophylactic fluid. Br. Med. J.1, 1461 (1897).
   Google Scholar
• Taylor J. Haffkine’s plague vaccine. Indian Med. Res. Memoirs27, 1–125 (1933).
   Google Scholar
• Meyer KF, Cavanaugh DC, Bartelloni PJ, Marshall JD Jr. Plague immunization. I. Past and present trends. J. Infect. Dis.129(Suppl), S13–S18 (1974).
   Google Scholar
• Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull. World Health Organ.42(5), 653–666 (1970).
   PubMed Web of Science ®Google Scholar
• Cavanaugh DC, Elisberg BL, Llewellyn CH et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J. Infect. Dis.129(Suppl.), S37–S40 (1974).
   PubMed Web of Science ®Google Scholar
• Cohen RJ, Stockard JL. Pneumonic plague in an untreated plague-vaccinated individual. JAMA202(4), 365–366 (1967).
   PubMed Web of Science ®Google Scholar
• Kolle W, Otto R. Weitere Untersuchungen uber die Pestimmunitat. Zeitschr. F. Hyg.48, 399–428 (1904).
   Google Scholar
• Strong RP. Vaccination against plague. Phillipine J. Sci.1, 181–190 (1906).
   Google Scholar
• Strong RP. Protective inoculation against plague. J. Med. Res.18, 325–346 (1908).
   PubMedGoogle Scholar
• Girard G. Immunity in plague. Results of 30 years of work on the ‘Pasteurella pestis Ev’ (Girard and Robic) strain Biol Med (Paris)52, 631–731 (1963).
   PubMedGoogle Scholar
• Meyer KF, Smith G, Foster L, Brookman M, Sung M. Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J. Infect. Dis.129(Suppl.), S85–S112 (1974).
   PubMed Web of Science ®Google Scholar
• Russell P, Eley SM, Hibbs SE et al. A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine13(16), 1551–1556 (1995).
   PubMed Web of Science ®Google Scholar
• Aleksandrov NI, Gefen NE, Gapochko KG et al. Study of a method of aerosol immunization with powdered plague vaccine in extensive population groups. Zh. Mikrobiol. Epidemiol. Immunobiol.40, 22–28 (1963).
   PubMedGoogle Scholar
• Baker EE, Sommer H, Foster LE, Meyer E, Meyer KF. Studies on immunization against plague. I. The isolation and characterization of the soluble antigen of Pasteurella pestis. J. Immunol.68, 131–145 (1952).
   PubMed Web of Science ®Google Scholar
• Ehrenkranz NJ, Meyer KF. Studies on immunization against plague. VIII. Study of three immunizing preparations in protecting primates against pneumonic plague. J. Infect. Dis.96, 138–144 (1955).
   PubMed Web of Science ®Google Scholar
• Andrews GP, Heath DG, Anderson GW Jr. Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect. Immun.64(6), 2180–2187 (1996).
   PubMed Web of Science ®Google Scholar
• Anderson GW, Jr. Worsham PL, Bolt CR et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis.Am. J. Trop. Med. Hyg.56(4), 471–473 (1997).
   PubMed Web of Science ®Google Scholar
• Worsham PL, Stein MP, Welkos SL. Construction of defined F1 negative mutants of virulent Yersinia pestis. Contrib. Microbiol. Immunol.13, 325–328 (1995).
   PubMedGoogle Scholar
• Burrows TW, Bacon GA. The basis of virulence in Pasteurella pestis: an antigen determining virulence. Br. J. Exp. Pathol.37, 481–493 (1956).
   PubMedGoogle Scholar
• Janssen WA, Lawton WD, Fukui GM, Surgalla MJ. The pathogenesis of plague. I. A study of the correlation between virulence and relative phagocytosis resistance of some strains of Pasteurella pestis. J. Infect. Dis.113, 139–143 (1963).
   PubMed Web of Science ®Google Scholar
• Lawton WD, Erdman RL, Surgalla MJ. Biosynthesis and purification of V and W antigen in Pateurella pestis. J. Immunol.91, 179–184 (1963).
   PubMed Web of Science ®Google Scholar
• Une T, Brubaker RR. Roles of V antigen in promoting virulence and immunity in yersiniae. J. Immunol.133(4), 2226–2230 (1984).
   PubMed Web of Science ®Google Scholar
• Sato K, Nakajima R, Hara F, Une T, Osada Y. Preparation of monoclonal antibody to V antigen from Yersinia pestis.Contrib. Microbiol. Immunol.12, 225–229 (1991).
   PubMedGoogle Scholar
• Nakajima R, Brubaker RR. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect. Immun.61(1), 23–31 (1993).
   PubMed Web of Science ®Google Scholar
• Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect. Immun.62(10), 4192–4201 (1994).
   PubMed Web of Science ®Google Scholar
• Price SB, Leung KY, Barve SS, Straley SC. Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis. J. Bacteriol.171(10), 5646–5653 (1989).
   PubMed Web of Science ®Google Scholar
• Leary SE, Williamson ED, Griffin KF et al. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun.63(8), 2854–2858 (1995).
   PubMed Web of Science ®Google Scholar
• Anderson GW Jr. Leary SE, Williamson ED et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect. Immun.64(11), 4580–4585 (1996).
   PubMed Web of Science ®Google Scholar
• Anderson GW Jr. Heath DG, Bolt CR, Welkos SL, Friedlander AM. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am. J. Trop. Med. Hyg.58(6), 793–799 (1998).
   PubMed Web of Science ®Google Scholar
• Hill J, Copse C, Leary S et al. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect. Immun.71(4), 2234–2238 (2003).
   PubMed Web of Science ®Google Scholar
• Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect. Immun.65(2), 446–451 (1997).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol.12(3–4), 223–230 (1995).
   PubMedGoogle Scholar
• Williamson ED, Sharp GJ, Eley SM et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine14(17–18), 1613–1619 (1996).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Eley SM, Stagg AJ et al. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine15(10), 1079–1084 (1997).
   PubMed Web of Science ®Google Scholar
• Jones SM, Day F, Stagg AJ, Williamson ED. Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine19(2–3), 358–366 (2000).
   PubMed Web of Science ®Google Scholar
• Heath DG, Anderson GW Jr, Mauro JM et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine16(11–12), 1131–1137 (1998).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Flick-Smith HC, Lebutt C et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect. Immun.73(6), 3598–3608 (2005).
   PubMed Web of Science ®Google Scholar
• Morris SR. Development of a recombinant vaccine against aerosolized plague. Vaccine,25(16), 3115–3117 (2007).
   PubMed Web of Science ®Google Scholar
• Abdy M. The ‘Animal Rule’. In: 5th Annual Biodefense Vaccines and Therapeutics Policy, Funding, and Development Conference Washington, DC, USA, 4–6 June 2007
   Google Scholar
• Bashaw J, Norris S, Weeks S et al. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin. Vaccine Immunol.14(5), 605–616 (2007).
   PubMedGoogle Scholar
• Goodin JL, Nellis DF, Powell BS et al. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1–V antigen fusion proteins for vaccination against plague. Protein Expr. Purif.53(1), 63–79 (2007).
   PubMed Web of Science ®Google Scholar
• DeBord KL, Anderson DM, Marketon MM et al. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect. Immun.74(8), 4910–4914 (2006).
   PubMed Web of Science ®Google Scholar
• Jones T, Adamovicz JJ, Cyr SL et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine24(10), 1625–1632 (2006).
   PubMed Web of Science ®Google Scholar
• Glynn A, Roy CJ, Powell BS et al. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect. Immun.73(8), 5256–5261 (2005).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Spiers ID et al. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J. Control Release63(1–2), 191–200 (2000).
   PubMed Web of Science ®Google Scholar
• Honko AN, Sriranganathan N, Lees CJ, Mizel SB. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun.74(2), 1113–1120 (2006).
   PubMed Web of Science ®Google Scholar
• Wang S, Heilman D, Liu F et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine22(25–26), 3348–3357 (2004).
   PubMed Web of Science ®Google Scholar
• Oyston PC, Williamson ED, Leary SE et al. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect. Immun.63(2), 563–568 (1995).
   PubMed Web of Science ®Google Scholar
• Titball RW, Howells AM, Oyston PC, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun.65(5), 1926–1930 (1997).
   PubMed Web of Science ®Google Scholar
• Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog.23(3), 167–179 (1997).
   PubMed Web of Science ®Google Scholar
• Garmory HS, Griffin KF, Brown KA, Titball RW. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine21(21–22), 3051–3057 (2003).
   PubMed Web of Science ®Google Scholar
• Yang X, Hinnebusch BJ, Trunkle T et al. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J. Immunol.178(2), 1059–1067 (2007).
   PubMed Web of Science ®Google Scholar
• Palin A, Chattopadhyay A, Park S et al. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine25(4), 741–750 (2007).
   PubMed Web of Science ®Google Scholar
• Chiuchiolo MJ, Boyer JL, Krause A et al. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J. Infect. Dis.194(9), 1249–1257 (2006).
   PubMed Web of Science ®Google Scholar
• Andrews GP, Strachan ST, Benner GE et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect. Immun.67(3), 1533–1537 (1999).
   PubMed Web of Science ®Google Scholar
• Matson JS, Durick KA, Bradley DS, Nilles ML. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol.5(1), 38 (2005).
   PubMed Web of Science ®Google Scholar
• Swietnicki W, Powell BS, Goodin J. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague. Protein Expr. Purif.42(1), 166–172 (2005).
   PubMed Web of Science ®Google Scholar
• Bubeck SS, Dube PH. Yersinia pestis CO92 δ yopH is a potent live, attenuated plague vaccine. Clin. Vaccine Immunol.14(9), 1235–1238 (2007).
   PubMedGoogle Scholar
• Flashner Y, Mamroud E, Tidhar A et al. Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect. Immun.72(2), 908–915 (2004).
   PubMed Web of Science ®Google Scholar
• Montminy SW, Khan N, McGrath S et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol.7(10), 1066–1073 (2006).
   PubMed Web of Science ®Google Scholar
• Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun.70(8), 4092–4098 (2002).
   PubMed Web of Science ®Google Scholar
• Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. Variation in lipid A structure in the pathogenic yersiniae. Mol. Microbiol.52(5), 1363–1373 (2004).
   PubMed Web of Science ®Google Scholar
• Green M, Rogers D, Russell P et al. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol. Med. Microbiol.23(2), 107–113 (1999).
   PubMed Web of Science ®Google Scholar
• Philipovskiy AV, Cowan C, Wulff-Strobel C et al. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect. Immun.73(3), 1532–1542 (2005).
   PubMed Web of Science ®Google Scholar
• Cowan C, Philipovskiy AV, Wulff-Strobel CR, Ye Z, Straley SC. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis. Infect. Immun.73(9), 6127–6137 (2005).
   PubMed Web of Science ®Google Scholar
• Weeks S, Hill J, Friedlander A, Welkos S. Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microb. Pathog.32(5), 227–237 (2002).
   PubMed Web of Science ®Google Scholar
• Pettersson J, Holmstrom A, Hill J et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol. Microbiol.32(5), 961–976 (1999).
   PubMed Web of Science ®Google Scholar
• Fields KA, Nilles ML, Cowan C, Straley SC. Virulence role of V antigen of Yersinia pestis at the bacterial surface. Infect. Immun.67(10), 5395–5408 (1999).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Flick-Smith HC, Waters E et al. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb. Pathog.42(1), 11–21 (2007).
   PubMed Web of Science ®Google Scholar
• Wong JF, Elberg SS. Cellular immune response to Yersinia pestis modulated by product(s) from thymus-derived lymphocytes. J. Infect. Dis.135(1), 67–78 (1977).
   PubMed Web of Science ®Google Scholar
• Pujol C, Grabenstein JP, Perry RD, Bliska JB. Replication of Yersinia pestis in interferon γ-activated macrophages requires ripA, a gene encoded in the pigmentation locus. Proc. Natl Acad. Sci. USA102(36), 12909–12914 (2005).
   PubMed Web of Science ®Google Scholar
• Elvin SJ, Williamson ED. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb. Pathog.37(4), 177–184 (2004).
   PubMed Web of Science ®Google Scholar
• Parent MA, Wilhelm LB, Kummer LW et al. γ interferon, tumor necrosis factor α, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect. Immun.74(6), 3381–3386 (2006).
   PubMed Web of Science ®Google Scholar
• Straley SC, Cibull ML. Differential clearance and host-pathogen interactions of YopE- and YopK- YopL- Yersinia pestis in BALB/c mice. Infect. Immun.57(4), 1200–1210 (1989).
   PubMed Web of Science ®Google Scholar
• Kerschen EJ, Cohen DA, Kaplan AM, Straley SC. The plague virulence protein YopM targets the innate immune response by causing a global depletion of NK cells. Infect. Immun.72(8), 4589–4602 (2004).
   PubMed Web of Science ®Google Scholar
• Sebbane F, Lemaitre N, Sturdevant DE et al. Adaptive response of Yersinia pestis to extracellular effectors of innate immunity during bubonic plague. Proc. Natl Acad. Sci. USA103(31), 11766–11771 (2006).
   PubMed Web of Science ®Google Scholar
• Alonso JM, Vilmer E, Mazigh D, Mollaret HH. Mechanisms of acquired resistance to plague in mice infected by Yersinia enterocolitica 03. Current Microbiology,4, 117–122 (1980).
   Web of Science ®Google Scholar
• Wake A, Sutoh Y. Mechanims of protection against virulent Yersinia pestis infection without participation of humoral antibody: H-2 restriction in athymic mouse model. Curr. Microbiol.8, 79–84 (1983).
   Web of Science ®Google Scholar
• Philipovskiy AV, Smiley ST. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect. Immun.75, 878–885 (2007).
   PubMed Web of Science ®Google Scholar